President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling nasty), or is at least thinking about it. These meds—which include Ozempic, ...

Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Fiber can support weight loss by increasing satiety hormones, slowing eating rate, and decreasing inflammation. The ...